Evidence map›Paper›PMID 27535741›Full record

ArticleBMC genomics2016

The beagle dog MicroRNA tissue atlas: identifying translatable biomarkers of organ toxicity.

Erik M Koenig, Craig Fisher, Hugues Bernard, Francis S Wolenski, Joseph Gerrein, Mary Carsillo, Matt Gallacher, Aimy Tse, Rachel Peters, Aaron Smith and 3 more

Abstract read
In one paragraph

Article in BMC genomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. The Rapidly Evolving X-linkedbioRxiv : the preprint server for biology · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Erik M KoenigTakeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA. Erik.Koenig@Takeda.com.
Craig FisherTakeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA.
Hugues BernardTakeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA.
Francis S WolenskiTakeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA.
Joseph GerreinTakeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA.
Mary CarsilloTakeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA.
Matt GallacherTakeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA.
Aimy TseTakeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA.
Rachel PetersTakeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA.
Aaron SmithEli Lilly and Company, 893 S. Delaware, Indianapolis, IN, 46285, USA.
Alexa MeehanTakeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA.
Stephen TirrellTakeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA.
Patrick KirbyTakeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNAs (miRNA) are varied in length, under 25 nucleotides, single-stranded noncoding RNA that regulate post-transcriptional gene expression via translational repression or mRNA degradation. Elevated levels of miRNAs can be detected in systemic circulation after tissue injury, suggesting that miRNAs are released following cellular damage. Because of their remarkable stability, ease of detection in biofluids, and tissue specific expression patterns, miRNAs have the potential to be specific biomarkers of organ injury. The identification of miRNA biomarkers requires a systematic approach: 1) determine the miRNA tissue expression profiles within a mammalian species via next generation sequencing; 2) identify enriched and/or specific miRNA expression within organs of toxicologic interest, and 3) in vivo validation with tissue-specific toxicants. While miRNA tissue expression has been reported in rodents and humans, little data exists on miRNA tissue expression in the dog, a relevant toxicology species. The generation and evaluation of the first dog miRNA tissue atlas is described here.

resultsAnalysis of 16 tissues from five male beagle dogs identified 106 tissue enriched miRNAs, 60 of which were highly enriched in a single organ, and thus may serve as biomarkers of organ injury. A proof of concept study in dogs dosed with hepatotoxicants evaluated a qPCR panel of 15 tissue enriched miRNAs specific to liver, heart, skeletal muscle, pancreas, testes, and brain. Dogs with elevated serum levels of miR-122 and miR-885 had a correlative increase of alanine aminotransferase, and microscopic analysis confirmed liver damage. Other non-liver enriched miRNAs included in the screening panel were unaffected. Eli Lilly authors created a complimentary Sprague Dawely rat miRNA tissue atlas and demonstrated increased pancreas enriched miRNA levels in circulation, following caerulein administration in rat and dog.

conclusionThe dog miRNA tissue atlas provides a resource for biomarker discovery and can be further mined with refinement of dog genome annotation. The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development.

Indexed as

Gene Expression ProfilingTranscriptomeAnimalsBiomarkersCluster AnalysisComputational BiologyDogsFemaleGene Expression RegulationHigh-Throughput Nucleotide SequencingMaleMicroRNAsMolecular Sequence AnnotationOrgan SpecificityBiomarkersMicroRNAs

Identifiers

PMID27535741
PMCPMC4989286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.